A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Conditions:   Asthma;   Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: AZD7594 inhalation powder (200 ?g);   Drug: AZD7594 inhalation powder (400 ?g);   Drug: AZD7594 pressurized inhalation suspension (200 ?g);   Drug: AZD7594 placebo inhalation powder;   Drug: AZD7594 placebo pressurized inhalation suspension
Sponsor:   AstraZeneca
Not yet recruiting – verified December 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

FDA Approves New Inhaler HFA Formulation for Asthma – Canada Drugs Online News – Market Press Release (press release)

FDA Approves New Inhaler HFA Formulation for Asthma – Canada Drugs Online News
Market Press Release (press release)
ProAir HFA provides you a fast relief when experiencing asthma, exercise-induced bronchospasm (EIB) and chronic obstructive pulmonary disease (COPD). It contains albuterol and is prescribed to patients not younger than 4 years of age.

View full post on asthma – Google News